AGP Executive Report

Perioperative Mental Health: A Stanford-led study in Anesthesiology reports a five-step “anesthesia dreaming” protocol that helps patients recall more positive, soothing dreams and boosts satisfaction, with a key element being about 10 minutes of low-stimulation time during emergence. Drug Policy & Access: A U.S. FTC settlement with CVS Caremark spotlights pharmacy benefit manager practices that inflate drug prices via rebates, aiming to redirect billions in savings to patients and push PBMs toward fairer reimbursement. Regulation Shake-Up: Trump’s executive order recommends splitting childhood vaccines into single-disease visits and presses states to narrow school requirements to a smaller federal list, raising major operational questions for primary care. Pharma Dealmaking: Jazz Pharmaceuticals agreed to buy Actio Biosciences for up to $1.32B to expand its epilepsy pipeline, including ABS-1230 for KCNT1-related pediatric epilepsy. Clinical Care Update: A JAMA Otolaryngology trial finds that a short post-tonsillectomy course of oral dexamethasone reduces pain and opioid use in children. Infectious Disease Watch: Suffolk County, New York, confirmed a fourth tularemia (“rabbit fever”) case on Long Island as tick-bite visits hit near-decade highs. Healthcare Innovation: North Carolina and nationwide efforts show AI is being integrated into care workflows, from diagnostics to drafting clinician communications.

Gene Therapy & CAR T Deals: Johnson & Johnson struck a major collaboration with Sail Biomedicines to develop in vivo CAR T for immune-mediated diseases, with up to $3.5B+ in potential value. Regulatory Watch: An FDA advisory panel voted against deramiocel for Duchenne cardiomyopathy, setting up an Aug. 22 decision. Oncology Pipeline: Akeso dosed the first patient in a Phase II trial of AK146D1 (TROP2/Nectin-4 bsADC) plus ivonescimab for advanced breast cancer. Rare Cancer Moves: Sobi added a rare lymphoma drug alliance with Innate Pharma, while Soligenix halted its topical CTCL therapy HyBryte after a Phase III miss. Infectious Disease: WHO urged a Phase III Ervebo vaccine trial against the Bundibugyo Ebola strain in the current outbreak. Healthcare Business: Society of Interventional Radiology launched an initiative to define IR’s value; RadNet reported “disproportionately higher” advanced imaging growth and raised guidance. Global Health & Access: Bangladesh is seeking new markets for pharmaceuticals and other sectors in New Zealand, aiming to diversify beyond garments. Patient Care & Systems: India opened a LE&RN-accredited one-stop lymphedema clinic at Apollo Athenaa.

FDA Narcolepsy Breakthrough: Takeda’s oral orexin agonist oveporexton (Orzeyful) won FDA approval for narcolepsy type 1 in adults, with RMAT designation also highlighted for Aspen Neuroscience’s sasineprocel. Cancer & Cell Therapy Debate: New discussion questions whether CAR T outcomes are shaped by patient selection, and how that affects evidence for earlier use in multiple myeloma. GLP-1 Cardiovascular Data: Database-backed findings suggest tirzepatide initiation in type 2 diabetes with ASCVD may lower major adverse cardiovascular events versus placebo proxy. Healthcare Access & Costs: A report on the ACA claims fraud drove enrollment drops, while critics point to higher premiums and deductibles leaving millions uninsured. Mental Health Services: UK mental health charities warn Northern Ireland’s strategy remains underfunded despite new UK crisis-service investment. Public Health Equity: WHO-linked analysis estimates heavy hepatitis B mother-to-child transmission in Africa and calls for higher birth-dose vaccination plus maternal antivirals. Rural Care Pressure: A commentary argues kidney value-based care hasn’t reduced hospital spending, and that the cost-driving hospitalization happens earlier than targets. Patient Safety in Practice: A study finds standard clinic schedules can push working patients out of outpatient alcohol recovery. Industry Watch: RadNet posted record quarterly revenue and guidance updates, while Depo-Provera litigation continues to grow over alleged safety warnings.

Medicine Access & Pricing: South Africa’s pharma industry warns of growing medicine shortages as regulated prices and rising costs squeeze manufacturers, with oil-price-linked cost pressure cited. Diabetes Affordability Policy: A U.S. bill (INSULIN Act) advances to cap private-insurance insulin at $35/month and targets alleged FDA citizen-petition tactics that can delay cheaper generics and biosimilars. Pharma Supply & Quality: Maharashtra FDA permanently cancels a Pune pharma firm’s licence after serious GMP lapses tied to six contaminated medicines. Diabetes Drug Competition: A Canadian-made generic Ozempic is poised to enter the market, aiming to boost local pharmaceutical sovereignty. Cancer Care: Phase 3 PSMAddition results show lutetium Lu 177 vipivotide tetraxetan added to standard therapy extends radiographic progression-free survival in PSMA-positive metastatic prostate cancer. Health Tech & AI: India’s health ministry releases an AI in MedTech knowledge paper outlining priorities to move AI from pilots to clinical scale, including data fragmentation and regulation. Public Health Systems: Nigeria’s NPHCDA maps “zero-dose” child hotspots to target immunisation outreach using an identify-enumerate-vaccinate approach. Wellness & Nutrition: New reporting highlights practical habits for steadier blood sugar, plus fermented drinks’ potential benefits and label/sugar caveats. Mental Health: Spokane wildfire coverage spotlights the mental health impact of smoke, shock, and “survival mode” after disasters. Research Advances: Studies link earlier allergen introduction to falling peanut allergy rates and explore dementia types via distinct immune inflammation patterns.

Dementia & Inflammation: A new meta-analysis links four common dementia types to distinct immune/inflammatory profiles, raising hopes for more targeted treatments. Public Health Access: Nigeria’s NPHCDA mapped “zero-dose” hotspots to guide targeted vaccination using an identify-enumerate-vaccinate approach. Drug Pricing & Patents: U.S. lawmakers advanced insulin cost caps ($35/month) and moved to curb FDA citizen-petition tactics that can delay generics and biosimilars. New Narcolepsy Option: The FDA approved Orzeyful (oveporexton), the first medicine aimed at treating the full symptom range of narcolepsy type 1 by restoring orexin signaling. Food Allergy Breakthrough: A study suggests omalizumab-facilitated oral immunotherapy can help many multi-food allergy patients start at maintenance dosing with fewer escalation steps. Gut Microbiome Therapy: Early results from “poop pill” fecal transplants indicate some severe peanut-allergy patients may gain tolerance, with antibiotics potentially improving transfer. Women’s Health: Research found type 2 diabetes is tied to more severe menopause symptoms, underscoring the need to manage cardiovascular risk during the transition. Care Delivery & Equity: Experts discuss how to expand access to bladder-sparing intravesical therapies despite logistical and reimbursement barriers.

FDA Watch: Moderna’s mRNA flu vaccine mFlusiva wins FDA approval for adults 50+, but trial data show higher Grade 3 reactions and only a narrow hospitalization benefit. Public Health: The CDC says the cyclospora outbreak tied to iceberg lettuce has expanded to 15 states, with nearly 6,400 illnesses reported and far higher counts suggested by local data. Healthcare Tech: Onvida Health earns KLAS recognition for improving electronic health record workflows, aiming to reduce clinician burnout by streamlining documentation. Policy & Access: CMS released an implementation timeline for No Surprises Act independent dispute resolution updates, clarifying timelines and coding details. Drugs & Litigation: The Ozempic lawsuit crisis keeps growing, with nearly 4,000 cases consolidated in MDL over alleged inadequate side-effect warnings. Nutrition & Wellness: WK Kellogg accelerates plans to remove artificial colors and BHT from cereals by end of 2026, shifting to natural-derived colors. Community Care: Leicester’s mental health overhaul includes a new emergency department for people in crisis plus more walk-in community centers. Digital Health in India: Ayushman Bharat’s Scan and Register service tops 25 crore OPD registrations via QR-based sharing of ABHA profiles.

Bladder Cancer Care: AHN is rolling out Inlexzo (formerly TAR-200), an indwelling gemcitabine system designed to extend local drug exposure for BCG-unresponsive NMIBC while avoiding systemic toxicity. Pediatric Oncology: A 5-year ELIANA analysis shows durable, manageable long-term results for tisagenlecleucel in pediatric/young adult B-ALL. CAR T Decision-Making: Experts discuss why early referral and careful patient selection matter in multiple myeloma, and how sequencing CAR T before bispecifics may improve outcomes. End-of-Life Access: Vancouver Coastal Health is reopening Cottage Hospice with upgrades and a new operating partnership to meet ongoing demand for palliative care. Pediatric Allergy Screening: Symptom-based screening in children with asthma found unexpectedly high eosinophilic esophagitis rates, supporting earlier evaluation. Healthcare Workforce Burnout: Cardiac CT specialist burnout is worsening, with calls for structural fixes beyond individual resilience. Pharma Deals & Delivery: Tarsus will acquire Alkeus for $450M to advance a Stargardt therapy; Amazon Pharmacy begins $50/month GLP-1 delivery for eligible Medicare patients. Public Health & Safety: A study flags high severe-disease risk among hospitalized children with acute respiratory tract infections, especially after transfers. Opioid Misuse Economics: A University of Utah evaluation finds mindfulness-based MORE could be highly cost-effective for opioid misuse and chronic pain.

Psychedelic PTSD Care: A new study finds high-dose psilocybin sessions for PTSD are mostly spent in silence, suggesting support is often quiet presence rather than talk therapy. Neurodegeneration in Psychosis: PET imaging links late-onset psychosis to tau buildup, pointing to hidden brain differences that may explain why symptoms vary. ADHD Medication Aftereffects: Stopping methylphenidate can disrupt sleep and activity rhythms long after discontinuation in animal research. Cancer Therapy Milestone: Replimune’s oncolytic virus therapy wins FDA approval for advanced melanoma with Opdivo, after prior setbacks. Immunotherapy Research: Zebrafish work ties gene-activity changes to spinal disc breakdown, hinting at future drug targets for back pain. Care Delivery & Staffing: Nurses protest CommonSpirit Health cuts tied to “safe births,” while a UK hospital phlebotomy team is honored for compassionate patient care. Food & Health Safety: Nigeria police step up efforts to curb sale of dead animals’ meat; separate reporting flags microplastics in blood as linked to severe heart attacks, though causation isn’t proven. Industry & Policy: The UK expands its Global Talent visa to over 100 research-focused companies, and new U.S. generic drug tariff rules are set to reshape pharma sourcing and manufacturing plans.

FDA & Vaccines: Moderna’s first mRNA flu vaccine for adults 50+ (mFlusiva) won FDA approval, adding a new option for seniors as flu hospitalizations stay high. Oncology Advances: MonumenTAL-6 data highlight a major risk reduction with teclistamab plus talquetamab in relapsed/refractory multiple myeloma, while FDA cleared Replimune (Tudriqev) with Opdivo for advanced melanoma after prior setbacks. Tech in Care: A small UC San Diego study found Apple Vision Pro could cut endoscopic tear-duct surgery time by about 19% and reduce surgeon workload. Policy & Access: CMS’s Medicaid work requirements rule sets a nationwide “community engagement” framework, but states will vary on exemptions and verification. Health Systems & Safety: Shared cardiac PET programs may expand access, and RFID tracking is being pitched to close hospital medication inventory gaps. Public Health Watch: Cyclospora investigations expanded across more states, with CDC-linked guidance urging caution with certain raw produce. Business Moves: Biogen completed its RayThera acquisition to bolster immunology assets.

Regulatory Overhaul (Medical Cannabis): The Bahamas is moving ahead with medical cannabis after signing with Metrc for a digital “seed-to-sale” tracking and licensing platform, plus e-prescription updates via an amended Pharmacy Act. FDA & Vaccines: Moderna’s mRNA seasonal flu vaccine (mFlusiva) is approved for adults 50+ in the U.S., with a faster, more flexible manufacturing path for future strains. RSV Prevention Expansion: The FDA accepted Merck’s sBLA to expand ENFLONSIA (clesrovimab-cfor) to prevent RSV lower respiratory tract disease in children under two at increased risk for their second season. Nephrology Treatment Shift: New discussion weighs where corticosteroids and RAS inhibitors fit now that sparsentan is FDA-approved for FSGS, including how it may displace RAS inhibitors for proteinuria reduction. Oncology Trial Momentum: Summit Therapeutics starts the global phase 2/3 HARMONi-GU1 trial testing ivonescimab plus enfortumab vedotin as first-line urothelial cancer therapy. Healthcare Operations & Safety: OhioHealth plans a $10.2M expansion doubling CT capacity, while interventional teams release an ALARA radiation-safety toolkit to reduce occupational exposure. Pharma Compliance Crackdown: India’s drug rules now let state authorities debar companies submitting fake or misleading data, with due process built in.

AI in Clinical Workflows: UnityPoint Health is rolling out ambient scribing, chart summarization, and real-time capacity tools to cut admin burden and help clinicians spend more time with patients. Labor & Care Access: Homecare workers in New York ended a second hunger strike after pushing the “No More 24” Act to limit home aide shifts to 12 hours. Rural Hospitals & Affordability: AHA argues healthcare costs start with having care close to home, warning rural hospital closures raise travel delays and community-wide economic strain. Medicare Advantage Dispute: A federal court allowed the AHA to file an amicus brief in a case challenging Aetna’s “level of severity” reimbursement policy. 340B Policy Push: Senators introduced bipartisan legislation to clarify 340B rules and add transparency and integrity requirements. Public Health Alerts: Orange County confirmed its first West Nile virus human case this year. Weight & Metabolic Support: Curative partnered with Wondr Health to expand digital weight management, including GLP-1 prescribing when eligible. Blood Supply Crunch: The American Red Cross declared a national blood supply crisis, limiting type O-positive distribution to protect critical care needs. Surgery Tech: Medtronic unveiled an FDA-cleared AI-assisted surgical computing platform aimed at real-time decision support in the operating room. Oncology Updates: NCCN added new listings for advanced breast and bladder cancer approaches using targeted agents and ctDNA MRD testing guidance.

GLP-1 Oversight Under Scrutiny: A secret shopper study found many GLP-1 telehealth sites move fast with little clinician oversight, sometimes issuing prescriptions in minutes and mailing compounded or branded meds despite missing or inconsistent patient details. Pipeline Pressure at Novo: Novo Nordisk’s CEO framed innovation as “survival” after a late-stage setback for ziltivekimab, signaling renewed focus on early pipeline bets. Big Pharma Deal Talk Meets Regulatory Reality: Rumors of a potential Bristol Myers Squibb–AstraZeneca merger surfaced amid Q2 earnings, with analysts flagging antitrust hurdles. Supply Chain & Manufacturing Moves: Medline reported strong med-surg growth and updated guidance; Lifecore Biomedical highlighted new late-stage pipeline wins; and Fujifilm and Taiho partnered to strengthen next-gen ADC manufacturing. Cancer & CNS Development: FDA breakthrough status was granted to Lilly’s pancreatic cancer drug olomorasib, while Supernus and Indivior announced a merger to build a CNS-focused company. Policy & Access: New Jersey proposed a multistate settlement over alleged generic drug price-fixing, and California’s Supreme Court ruled Gilead had no duty to bring a newer HIV drug to market sooner.

FDA Watch: July’s FDA moves span primary care and screening, including Merck’s enlicitide oral PCSK9 inhibitor for LDL-C, new blood-based colorectal cancer screening options, and expanded molecular testing for vaginitis. Women’s Heart Health: A McGill-led model aims to flag cardiovascular risk earlier in reproductive-age women by adding pregnancy-related factors missing from older calculators. Infectious Disease Policy: Experts warn a new Trump policy ending federally funded “dangerous gain-of-function” research could weaken outbreak preparedness despite stated biosecurity goals. Cancer Care Updates: Real-world data links early remdesivir to lower graft loss in kidney transplant patients with COVID-19; in pancreatic cancer, chemotherapy is tied to reduced severe pain; and FDA breakthrough status was granted for olomorasib in KRAS G12C+ advanced pancreatic cancer. Healthcare Workforce: Maine expands short-term training partnerships with community colleges to speed up hiring for roles like medical assistants and EMTs. Public Health & Safety: Wildfire smoke exposure was associated with more ED migraine visits, and Chipotle removed jalapeños tied to a Minnesota salmonella outbreak.

FDA & Rare Disease: FDA accepted Saol Therapeutics’ SL1009 (DCA) resubmission for pyruvate dehydrogenase complex deficiency, setting a Dec. 30, 2026 PDUFA date. Drug Pipeline Updates: MSD’s tulisokibart (TL1A) hit in hidradenitis suppurativa but failed in systemic sclerosis-associated interstitial lung disease, ending that study. Cancer & Diagnostics: Curium agreed to buy radiopharma rival Lantheus for up to $8B, aiming to expand theranostics and U.S. radiodiagnostics reach. AI in Healthcare: Korea’s health ministry will fund six AI medical-device consortiums to speed clinical validation and real-world adoption. Policy & Access: Wales health board strike action has led to tens of thousands of missed health visitor appointments. Consumer Protection: Michigan’s Supreme Court ruling revives the state’s ability to pursue insulin-pricing claims under the consumer protection act. Clinical Research & Trials: A study warns NICE breast cancer referral criteria may miss up to 95% of younger women at risk. Weight & Brain Biology: Research links weight regain after dieting to brain-driven fat defense mechanisms. Healthcare Workforce: Radiology staffing shortages are expected to keep pushing teleradiology growth.

Physician Trust vs Patient AI Use: A new Annals of Internal Medicine discussion links falling trust in doctors to the rise of chatbot-first care, arguing trust is shaped by how fast and accessible clinicians feel in real workflows. Food Safety Crisis: Michigan confirmed the first Cyclospora outbreak deaths as cases top 11,000 nationwide, with CDC/FDA tracing many illnesses to iceberg lettuce tied to Taylor Farms and prompting recalls. Cancer Immunotherapy Momentum: Multiple myeloma coverage highlights an “immunotherapy deluge,” with MonumenTAL-6 showing major progression and death risk reductions using teclistamab plus talquetamab. Pharma Deal Shock: Reports of AstraZeneca and Bristol Myers holding merger talks sent AstraZeneca shares down sharply, raising questions about strategy and antitrust risk. Clinical Trial Watch: A JAMA study found sodium bicarbonate didn’t improve outcomes in in-hospital cardiac arrest, challenging a long-standing resuscitation habit. Regulatory/Research Oversight: A hidden gene-editing trial death in China is renewing calls for stronger safety disclosure and consent standards. Healthcare Operations: UChicago Medicine Northwest Indiana released its first community health needs assessment, aiming to steer partnerships toward local priorities.

Prenatal Opioid Risks: A new review links prenatal opioid exposure to worse vision, more attention and hyperactivity problems, and lower cognitive performance in children. Gender-Affirming Care Access: Penn State Health stopped providing certain care for a transgender teen, citing federal directives after a Trump executive order, forcing a switch to a new doctor. Pharma Mega-Merger Buzz: AstraZeneca and Bristol Myers Squibb held early talks about a possible merger, but investors and analysts flag major overlap and antitrust hurdles. Leadership Shake-Up at BioNTech/Sobi: BioNTech appointed Sobi CEO Guido Oelkers as incoming CEO, while Sobi confirmed his step-down. US Antitrust Settlements: Sandoz agreed to pay $450m to settle US state antitrust claims tied to alleged price-fixing. Cybersecurity in Biopharma: Amgen disclosed a cybersecurity breach with patient health information potentially exfiltrated from cloud storage. Healthcare Policy/Access: India’s hospital groups pushed back on insurer guidance for fever admissions, saying clinical judgment should drive decisions. Clinical Care Evidence: UK trial results suggest compression wraps may heal venous leg ulcers more slowly than established evidence-based options. Rare Disease Trial Move: Can-Fite submitted a Phase 2 protocol to test piclidenoson for Lowe syndrome at Bambino Gesù Children’s Hospital. 340B Compliance Focus: HealthTrust held its 340B Summit amid proposed rebate model changes, contract pharmacy restrictions, and audit scrutiny.